Spruce Biosciences (SPRB) Retained Earnings (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Retained Earnings of -$301.5 million for Q1 2026, down 14.2% year-over-year from -$351.4 million in Q1 2025, and down 4.24% quarter-over-quarter from -$289.2 million in Q4 2025.
Spruce Biosciences (SPRB) Retained Earnings (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Retained Earnings for 8 consecutive years, with -$301.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 14.2% year-over-year to -$301.5 million; the TTM figure through Mar 2026 stood at -$301.5 million (down 14.2% YoY), while the FY2025 annual figure was -$289.2 million, down 15.57% from the prior year.
- Retained Earnings slipped to -$301.5 million in Q1 2026 per SPRB's latest filing, from -$289.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$114.9 million in Q1 2022 and bottomed at -$301.5 million in Q1 2026.
- Historically, Retained Earnings has averaged -$208.8 million across 5 years, with a median of -$208.9 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 62.45% — and 2026, when it retreated 14.2%.
- Spruce Biosciences' Retained Earnings stood at -$149.3 million in 2022, then plunged by 32.09% to -$197.2 million in 2023, then retreated by 26.89% to -$250.3 million in 2024, then declined by 15.57% to -$289.2 million in 2025, then fell by 4.24% to -$301.5 million in 2026.
- Business Quant data shows SPRB's Retained Earnings at -$301.5 million in Q1 2026, -$289.2 million in Q4 2025, and -$274.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 4.38 Bn |
| 10 | Spruce Biosciences | 123.98 Mn | 123.98 Mn | - | -317.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -317.73 Mn |
| Mar 31, 2026 | -301.50 Mn |
| Dec 31, 2025 | -289.23 Mn |
| Sep 30, 2025 | -274.60 Mn |
| Jun 30, 2025 | -266.38 Mn |
| Mar 31, 2025 | -264.00 Mn |
| Dec 31, 2024 | -250.27 Mn |
| Sep 30, 2024 | -226.70 Mn |
| Jun 30, 2024 | -218.00 Mn |
| Mar 31, 2024 | -208.86 Mn |
| Dec 31, 2023 | -197.23 Mn |
| Sep 30, 2023 | -187.30 Mn |
| Jun 30, 2023 | -174.93 Mn |
| Mar 31, 2023 | -162.10 Mn |
| Dec 31, 2022 | -149.31 Mn |
| Sep 30, 2022 | -138.17 Mn |
| Jun 30, 2022 | -126.80 Mn |
| Mar 31, 2022 | -114.90 Mn |
| Dec 31, 2021 | -103.13 Mn |
| Sep 30, 2021 | -93.95 Mn |